Diabetes drug metformin tested as possible CLL treatment
NCT ID NCT01750567
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 pilot study tested the diabetes drug metformin in 37 people with chronic lymphocytic leukemia (CLL) that had come back after treatment, or in untreated CLL with a specific genetic change (11q deletion). The goal was to see if metformin could slow the cancer's growth. Metformin is cheap and generally safe, but this was a small, early study, so results are not conclusive.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Metformin (Glucophage), a diabetes drug
What this could lead to
If it works, this could point toward a new, inexpensive, and well-tolerated treatment option for certain types of chronic lymphocytic leukemia.
What could go wrong
This is a small, early-phase pilot study with only 37 participants. Metformin is not a standard cancer treatment, and it may not slow the disease or may cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109, United States